Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Motif begins dosing for REVIVE trials
April 2016
EDIT CONNECT

SHARING OPTIONS:

LONDON—Motif Bio plc recently dosed the first patient in two Phase 3 clinical trials for iclaprim, its lead antibiotic candidate for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). The REVIVE trials will evaluate iclaprim's efficacy and safety compared to the antibiotic vancomycin for the treatment of ABSSSIs. The primary endpoint for will be at least a 20-percent reduction in lesion size at 48 to 72 hours after treatment, and the key secondary endpoint is clinical cure at one to two weeks after treatment.
 
“This is an important milestone for Motif that keeps us on track to complete the trials in the second half 2017. Iclaprim has the potential to be a major addition to the armamentarium of antibiotics much needed for the treatment of serious and life-threatening infections caused by multidrug-resistant bacteria in hospitalized patients,” said Graham Lumsden, Motif's CEO.
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.